Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases.
Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases.
OncoDNA SA is a Belgium-based company specializing in precision medicine for cancer treatment and genetic diseases. Founded in 2012, it leverages over 60 years of expertise in medical diagnostics, particularly in DNA sequencing and oncology analyses. The company offers a range of solutions, including OncoDEEP, a comprehensive theranostics tool for solid tumors that integrates DNA, RNA, and protein analysis to assist oncologists in making informed treatment decisions. Additionally, OncoDEEP&TRACE allows for the profiling of both solid and liquid biopsies, while OncoTRACE provides a personalized, non-invasive blood test for monitoring tumor progression and treatment efficacy. OncoSHARE facilitates collaboration among patients, oncologists, and the oncology community by streamlining sample management and data sharing. OncoDNA distributes its products both locally in Belgium and globally, supporting clinical guidance and research in oncology and genetic disorders.
Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.
Ogeda SA, a clinical-stage drug discovery company, invents and develops small molecule drugs targeting G-Protein Coupled Receptors. It offers fezolinetant (ESN364), a Phase II clinical development product for the treatment of women’s health disorders; NK3 antagonists for the treatment of hormone-dependent pathologies in women's health; and products for endocrine, CNS/inflammatory disorders. Ogeda SA was formerly known as Euroscreen SA and changed its name to Ogeda SA in October 2016. The company was founded in 1994 and is based in Gosselies, Belgium. It has a meeting facility in Brussels, Belgium; and an additional office in Paris, France. Ogeda SA operates as a subsidiary of Astellas Pharma Inc.
Trod Medical S.A. is a medical equipment and surgical device manufacturer founded in 2006, with headquarters in Leuven, Belgium, and a presence in the Tampa Bay area, USA. The company specializes in developing innovative ablation technologies, particularly focusing on radiofrequency (RF) ablation devices. Trod Medical's flagship product, the EncageTM, is a disruptive percutaneous RF device that enables precise tissue ablation, significantly reducing collateral damage—a critical concern in treatments for conditions such as prostate cancer. With prostate cancer being one of the most prevalent cancers, affecting approximately 240,000 new patients annually in the United States, Trod Medical's technology addresses the limitations of conventional treatments that often lead to severe side effects, including erectile dysfunction and urinary incontinence. The company aims to enhance patient outcomes through its advanced medical devices designed for the focal ablation of soft tissues.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.
Private Equity Round in 2012
Ogeda SA, a clinical-stage drug discovery company, invents and develops small molecule drugs targeting G-Protein Coupled Receptors. It offers fezolinetant (ESN364), a Phase II clinical development product for the treatment of women’s health disorders; NK3 antagonists for the treatment of hormone-dependent pathologies in women's health; and products for endocrine, CNS/inflammatory disorders. Ogeda SA was formerly known as Euroscreen SA and changed its name to Ogeda SA in October 2016. The company was founded in 1994 and is based in Gosselies, Belgium. It has a meeting facility in Brussels, Belgium; and an additional office in Paris, France. Ogeda SA operates as a subsidiary of Astellas Pharma Inc.
Trinean is a Belgium based technology provider, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes UV/VIS spectrometers for biomolecule quantification. The DropSense™16 and DropSense™96, analyzing up to 16 and 96 samples resp., use microfluidic chips for standardized sample analysis (DropPlates™ and Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.
Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.
Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.
Trinean is a Belgium based technology provider, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes UV/VIS spectrometers for biomolecule quantification. The DropSense™16 and DropSense™96, analyzing up to 16 and 96 samples resp., use microfluidic chips for standardized sample analysis (DropPlates™ and Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.